COMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder George Jay Goldsmith Sells 23,881 Shares

COMPASS Pathways plc (NASDAQ:CMPS) major shareholder George Jay Goldsmith sold 23,881 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $8.53, for a total value of $203,704.93. Following the sale, the insider now directly owns 3,986,523 shares of the company’s stock, valued at $34,005,041.19. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

George Jay Goldsmith also recently made the following trade(s):

• On Monday, April 1st, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The shares were sold at an average price of $8.96, for a total value of $230,720.00.
• On Tuesday, March 12th, George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock. The shares were sold at an average price of $10.58, for a total value of $166,529.20.
• On Monday, January 22nd, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The shares were sold at an average price of $8.35, for a total value of $215,012.50.
• On Friday, January 19th, George Jay Goldsmith sold 20,205 shares of COMPASS Pathways stock. The shares were sold at an average price of $7.99, for a total value of $161,437.95.

COMPASS Pathways Stock Performance

NASDAQ CMPS opened at $8.42 on Friday. The stock has a market capitalization of $521.53 million, a price-to-earnings ratio of -3.52 and a beta of 2.48. The company has a current ratio of 13.33, a quick ratio of 13.33 and a debt-to-equity ratio of 0.14. The business’s 50 day moving average is $9.98 and its two-hundred day moving average is $8.34. COMPASS Pathways plc has a 12-month low of $5.01 and a 12-month high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). Research analysts expect that COMPASS Pathways plc will post -2.4 EPS for the current year.

Analyst Ratings Changes

Several research firms have issued reports on CMPS. Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a research report on Thursday. HC Wainwright reiterated a “buy” rating and set a $120.00 target price on shares of COMPASS Pathways in a research report on Friday, March 1st. Finally, Morgan Stanley began coverage on COMPASS Pathways in a research report on Monday, April 1st. They set an “overweight” rating and a $30.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $47.40.

Institutional Investors Weigh In On COMPASS Pathways

A number of institutional investors and hedge funds have recently modified their holdings of the company. LPL Financial LLC grew its holdings in shares of COMPASS Pathways by 7.6% in the 2nd quarter. LPL Financial LLC now owns 11,055 shares of the company’s stock worth $120,000 after acquiring an additional 782 shares during the period. Raymond James & Associates grew its holdings in shares of COMPASS Pathways by 4.1% in the 1st quarter. Raymond James & Associates now owns 34,435 shares of the company’s stock worth $444,000 after acquiring an additional 1,341 shares during the period. TAP Consulting LLC grew its holdings in shares of COMPASS Pathways by 14.7% in the 3rd quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock worth $95,000 after acquiring an additional 1,645 shares during the period. Putnam Investments LLC grew its holdings in shares of COMPASS Pathways by 0.8% in the 4th quarter. Putnam Investments LLC now owns 250,155 shares of the company’s stock worth $2,189,000 after acquiring an additional 1,972 shares during the period. Finally, UBS Group AG grew its holdings in shares of COMPASS Pathways by 46.6% in the 1st quarter. UBS Group AG now owns 6,289 shares of the company’s stock worth $62,000 after acquiring an additional 1,998 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.